Shusterman N H, Wasserstein A G, Morrison G, Audet P, Fallon M D, Kaplan F
Am J Med. 1987 Jun;82(6):1148-56. doi: 10.1016/0002-9343(87)90217-8.
To assess the effect of different dialysis modalities on renal osteodystrophy, a controlled study was performed in six patients undergoing continuous ambulatory peritoneal dialysis and six hemodialysis-treated patients. All patients were enrolled at the initiation of dialysis, and age, sex, cause of renal failure, prior treatment of renal osteodystrophy, and baseline serum and bone histologic variables were similar in the two groups. After initial blood samples and bone biopsy specimens (with double-tetracycline labels) were obtained, renal osteodystrophy in both groups received comparable treatment with aluminum hydroxide to maintain serum phosphorus levels between 3.5 and 5.5 mg/dl, and with calcium carbonate and calcitriol to maintain total serum calcium levels between 10 and 11 mg/dl. Blood and bone samples were obtained again after nine months. All patients were asymptomatic at the beginning and end of the study. Phosphorus values were well controlled, and total calcium increased similarly in both groups. Although ionized calcium levels increased in both groups, the final level was higher in hemodialysis-treated patients than in patients undergoing continuous ambulatory peritoneal dialysis (2.82 +/- 0.07 meq/liter and 2.5 +/- 0.05 meq/liter, respectively; p = 0.005). Amino-terminal parathyroid hormone levels normalized in both groups, and histologic improvement of osteitis fibrosa occurred in a similar proportion of patients in both groups; however, quantitative improvement was greater in the hemodialysis-treated patients. Osteomalacia, assessed qualitatively and by dynamic histomorphometric measurements, was ameliorated to a much greater degree in patients undergoing continuous ambulatory peritoneal dialysis compared with hemodialysis-treated patients. Bone aluminum staining was absent in all biopsy specimens. Overall, bone histologic findings improved to a greater degree in patients undergoing continuous ambulatory peritoneal dialysis. When patients undergoing continuous ambulatory peritoneal dialysis or hemodialysis and receiving similar treatment for renal osteodystrophy were compared, patients treated with continuous ambulatory peritoneal dialysis appeared to have a greater improvement in their metabolic bone disease.
为评估不同透析方式对肾性骨营养不良的影响,对6例接受持续性非卧床腹膜透析的患者和6例接受血液透析治疗的患者进行了一项对照研究。所有患者均在透析开始时入组,两组患者的年龄、性别、肾衰竭病因、既往肾性骨营养不良治疗情况以及基线血清和骨组织学变量相似。在获取初始血样和骨活检标本(带有双四环素标记)后,两组肾性骨营养不良患者接受了类似的治疗,使用氢氧化铝维持血清磷水平在3.5至5.5mg/dl之间,使用碳酸钙和骨化三醇维持血清总钙水平在10至11mg/dl之间。9个月后再次获取血样和骨样。研究开始和结束时所有患者均无症状。磷值得到良好控制,两组总钙水平均有类似升高。尽管两组患者的离子钙水平均升高,但接受血液透析治疗的患者最终水平高于接受持续性非卧床腹膜透析的患者(分别为2.82±0.07meq/升和2.5±0.05meq/升;p = 0.005)。两组患者的氨基末端甲状旁腺激素水平均恢复正常,两组中类似比例的患者纤维性骨炎组织学有所改善;然而,接受血液透析治疗的患者在定量改善方面更明显。通过定性和动态组织形态计量学测量评估的骨软化症,与接受血液透析治疗的患者相比,接受持续性非卧床腹膜透析的患者改善程度更大。所有活检标本均未发现骨铝染色。总体而言,接受持续性非卧床腹膜透析的患者骨组织学结果改善程度更大。当比较接受持续性非卧床腹膜透析或血液透析并接受类似肾性骨营养不良治疗的患者时,接受持续性非卧床腹膜透析治疗的患者其代谢性骨病似乎改善更大。